BiomX to Present at the H.C. Wainwright 26th Annual Global Investment Conference
BiomX Inc. (NYSE American: PHGE), a clinical-stage company developing novel phage therapies targeting specific pathogenic bacteria, has announced its participation in the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
BiomX Inc. (NYSE American: PHGE), a clinical-stage company developing novel phage therapies targeting specific pathogenic bacteria, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event is scheduled for September 9-11, 2024, at the Lotte New York Palace Hotel.
Key details include:
- CEO Jonathan Solomon will present a corporate overview
- Presentation Date: September 9, 2024
- Time: Available on-demand from 7:00 AM ET
- Webcast link provided for virtual attendance
- Replay available on BiomX's website for 90 days
Mr. Solomon will also be available for one-on-one meetings during the conference. Interested parties can register and request meetings through the provided link.
Details
News Market Reaction – PHGE
The recorded move for PHGE in the trading session of this news was +1.77%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
GAITHERSBURG, Md., Sept. 04, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, announces today that Jonathan Solomon, Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 26th Annual Global Investment Conference. The conference is being held on September 9 - 11, 2024 at the Lotte New York Palace Hotel.
| Presentation Date: | September 9, 2024 | |
| Time: | Available on-demand starting at 7:00 AM ET | |
| Webcast Link: | https://journey.ct.events/view/d258dc7c-4d95-483c-9e0e-be6af1e9343d |
A replay of the presentation can be found on the Company’s website under Events & Presentations and will be available for 90 days: https://ir.biomx.com/news-events
Mr. Solomon will be available for one-on-one meetings throughout the conference. To request a meeting and to register for the conference, click here: https://hcwevents.com/annualconference/
About BiomX
BiomX is a clinical-stage company leading the development of natural and engineered phage cocktails and personalized phage treatments designed to target and destroy harmful bacteria for the treatment of chronic diseases with substantial unmet needs. BiomX discovers and validates proprietary bacterial targets and applies its BOLT (“BacteriOphage Lead to Treatment”) platform to customize phage compositions against these targets. For more information, please visit www.biomx.com, the content of which does not form a part of this press release.
Contacts:
BiomX, Inc.
Assaf Oron
+97254-2228901
assafo@biomx.com
INVESTORS:
CORE IR
Peter Seltzberg
peters@coreir.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.